BioXcel Therapeutics Inc.
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company’s commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
/ 
Frequently asked questions
To buy BioXcel Therapeutics Inc. stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for BioXcel Therapeutics Inc. by name or ticker, choose the number of shares, and place your order.
The ticker symbol for BioXcel Therapeutics Inc. is BTAI:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
BioXcel Therapeutics Inc. has its primary listing on NASDAQ (Small cap). You can trade BioXcel Therapeutics Inc. with a Saxo account, alongside thousands of other stocks worldwide.
Yes, BioXcel Therapeutics Inc. is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include BioXcel Therapeutics Inc. as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like BioXcel Therapeutics Inc..